Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries....
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2018-03-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/27/147/170098.full |
id |
doaj-40eb3078a0504395acb84e12bac7f71e |
---|---|
record_format |
Article |
spelling |
doaj-40eb3078a0504395acb84e12bac7f71e2020-11-25T00:39:58ZengEuropean Respiratory SocietyEuropean Respiratory Review0905-91801600-06172018-03-012714710.1183/16000617.0098-20170098-2017Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?Arnaud Boyer0Eddy Pasquier1Pascale Tomasini2Joseph Ciccolini3Laurent Greillier4Nicolas Andre5Fabrice Barlesi6Celine Mascaux7 Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France Aix Marseille University, Assistance Publique des Hôpitaux de Marseille, Dept of Haematology and Paediatric Oncology, Marseille, France Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille Cancer Research Centre), Inserm UMR1068, CNRS UMR7258 and Aix-Marseille University UM105, Marseille, France Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France Centre de Recherche en Cancérologie de Marseille (CRCM, Marseille Cancer Research Centre), Inserm UMR1068, CNRS UMR7258 and Aix-Marseille University UM105, Marseille, France Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries. Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost. This is critical in low- and middle-income countries where access to expensive drugs is limited. This review assesses the published preclinical and clinical data about drug repurposing in MPM. In this review, we identified 11 therapeutic classes that could be repositioned in mesothelioma. Most of these treatments have been evaluated in vitro, half have been evaluated in vivo in animal models of MPM and only three (i.e. valproate, thalidomide and zoledronic acid) have been investigated in clinical trials, with limited benefits so far. Efforts could be coordinated to pursue further investigations and test promising drugs identified in preclinical experiments in appropriately designed clinical trials.http://err.ersjournals.com/content/27/147/170098.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Arnaud Boyer Eddy Pasquier Pascale Tomasini Joseph Ciccolini Laurent Greillier Nicolas Andre Fabrice Barlesi Celine Mascaux |
spellingShingle |
Arnaud Boyer Eddy Pasquier Pascale Tomasini Joseph Ciccolini Laurent Greillier Nicolas Andre Fabrice Barlesi Celine Mascaux Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? European Respiratory Review |
author_facet |
Arnaud Boyer Eddy Pasquier Pascale Tomasini Joseph Ciccolini Laurent Greillier Nicolas Andre Fabrice Barlesi Celine Mascaux |
author_sort |
Arnaud Boyer |
title |
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
title_short |
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
title_full |
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
title_fullStr |
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
title_full_unstemmed |
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
title_sort |
drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
publisher |
European Respiratory Society |
series |
European Respiratory Review |
issn |
0905-9180 1600-0617 |
publishDate |
2018-03-01 |
description |
Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries. Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost. This is critical in low- and middle-income countries where access to expensive drugs is limited. This review assesses the published preclinical and clinical data about drug repurposing in MPM. In this review, we identified 11 therapeutic classes that could be repositioned in mesothelioma. Most of these treatments have been evaluated in vitro, half have been evaluated in vivo in animal models of MPM and only three (i.e. valproate, thalidomide and zoledronic acid) have been investigated in clinical trials, with limited benefits so far. Efforts could be coordinated to pursue further investigations and test promising drugs identified in preclinical experiments in appropriately designed clinical trials. |
url |
http://err.ersjournals.com/content/27/147/170098.full |
work_keys_str_mv |
AT arnaudboyer drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT eddypasquier drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT pascaletomasini drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT josephciccolini drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT laurentgreillier drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT nicolasandre drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT fabricebarlesi drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair AT celinemascaux drugrepurposinginmalignantpleuralmesotheliomaabreathoffreshair |
_version_ |
1725292124086206464 |